COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00780182
Recruitment Status : Completed
First Posted : October 27, 2008
Last Update Posted : February 2, 2010
National Institutes of Health (NIH)
Information provided by:

Brief Summary:
The purpose of this study is to compare the bioavailability of CMX001 when administered as a tablet vs a solution and to determine the effect of a high-fat meal on CMX001 bioavailability.

Condition or disease Intervention/treatment Phase
Healthy Drug: CMX001 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Randomized, 3-Way Crossover, Single-Dose Study in Healthy Volunteers Comparing the Bioavailability of CMX001 (HDP-Cidofovir Conjugate) Delivered as a Tablet Formulation vs a Solution Formulation and the Effect of Food on CMX001 Bioavailability
Study Start Date : October 2008
Actual Primary Completion Date : December 2008
Actual Study Completion Date : January 2009

Arm Intervention/treatment
Experimental: 1
All subjects will receive three 40mg doses of CMX001 as 1)solution fasted, 2)tablet fasted and 3)tablet following a high-fat breakfast. The order in which each subject receives each of the doses will be determined by a randomization code.
Drug: CMX001
CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted

Primary Outcome Measures :
  1. AUC and Cmax of CMX001 and cidofovir [ Time Frame: Each of 3 doses ]

Secondary Outcome Measures :
  1. Clinical and laboratory endpoints and adverse events [ Time Frame: Throughout the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy males and non-childbearing females 18-55 years old

Exclusion Criteria:

  • Use of an investigational drug and/or treatment within 30 days prior to enrollment.
  • Positive HIV, Hepatitis B or Hepatitis C test result
  • Tobacco user
  • History of GI disease or disorder
  • History of positive fecal occult blood test (FOBT)
  • Body Mass Index (BMI) > 30 or < 18, or body weight < 50 kg
  • Prior abdominal or pelvic surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00780182

Layout table for location information
United States, North Carolina
AAI Pharma
Rtp, North Carolina, United States, 27709
Sponsors and Collaborators
National Institutes of Health (NIH)
Layout table for investigator information
Principal Investigator: Evin H Sides, III, MD AAIPharma
Layout table for additonal information
Responsible Party: Neil Frazer/ Chief Medical Officer, Chimerix Identifier: NCT00780182    
Other Study ID Numbers: CMX001-103
First Posted: October 27, 2008    Key Record Dates
Last Update Posted: February 2, 2010
Last Verified: February 2010
Keywords provided by Chimerix: